38
Participants
Start Date
January 6, 2022
Primary Completion Date
April 4, 2022
Study Completion Date
April 7, 2022
Convalescent plasma
The intervention group will receive 200 or 400 mL of high-titer COVID-19 convalescent plasma, ABO compatible with the patient, within 24 hours of randomization.
Standard of care
The active comparator group will receive oxygen supplementation, corticoids, antiretrovirals, and/or monoclonal antibodies according to the institutional protocol.
Maternidade e Cirurgia Nossa Senhora do Rocio/ SA - Hospital do Rocio, Campo Largo
Centro de Hematologia e Hemoterapia do Paraná - Hemepar
UNKNOWN
Fundação Oswaldo Cruz, Instituto Carlos Chagas, ICC Paraná
UNKNOWN
Science Valley Research Institute
OTHER
Tânia Portella Costa
OTHER